Patients with Still's disease will continue to participate in a phase III clinical trial to evaluate the safety and immunogenicity of GNR-086, taken by patients who have completed participation in the CAN-AOSD-III clinical trial, sponsored by GENERIUM JSC, Russia
The beginning of the GNR086-AOSD0X study is a continuation of CAN-AOSD-III
- Super User
- Trials
- Read Time: 1 min
- Hits: 0
Our partners
